ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 190 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $90,737 | -18.8% | 16,649 | 0.0% | 0.00% | – |
| Q2 2023 | $111,715 | -24.0% | 16,649 | 0.0% | 0.00% | -100.0% |
| Q1 2023 | $147,011 | +15.6% | 16,649 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $127,198 | +38.3% | 16,649 | +29.1% | 0.00% | 0.0% |
| Q3 2022 | $92,000 | -11.5% | 12,894 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $104,000 | -41.9% | 12,894 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $179,000 | -53.9% | 12,894 | -6.9% | 0.00% | -50.0% |
| Q4 2021 | $388,000 | +8.7% | 13,845 | +31.7% | 0.00% | 0.0% |
| Q3 2021 | $357,000 | -16.8% | 10,511 | +0.1% | 0.00% | 0.0% |
| Q2 2021 | $429,000 | +2.1% | 10,500 | +0.7% | 0.00% | 0.0% |
| Q1 2021 | $420,000 | -38.7% | 10,423 | -10.0% | 0.00% | -50.0% |
| Q4 2020 | $685,000 | +69.6% | 11,579 | +39.4% | 0.00% | +33.3% |
| Q3 2020 | $404,000 | +0.5% | 8,308 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $402,000 | – | 8,308 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
| Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
| Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
| Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
| VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
| Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
| DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
| ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
| Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
| Triatomic Management LP | 102,889 | $560,745 | 0.39% |